NCT07077512 2026-01-21
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
3 trialsNCT05280626 2022-03-15
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Not yet recruiting
NCT04659434 2020-12-09
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown